Summit Therapeutics 的 ivonescimab 在 NSCLC 试验中优于 Keytruda，推动份额飙升。 Summit Therapeutics' ivonescimab outperforms Keytruda in NSCLC trial, driving share surge.
由于艾沃内西玛在非小细胞肺癌 (NSCLC) 第三阶段临床试验中的有前景表现, Summit Therapeutics 的股价今年升了近 900%,超过了 Nvidia 的 137% 的增长. Summit Therapeutics' shares have surged nearly 900% this year, outpacing Nvidia's 137% increase, driven by the promising performance of ivonescimab in a phase 3 clinical trial for non-small cell lung cancer (NSCLC). 这药比Merck的Keytruda效果更好, 这是目前的护理标准。 The drug showed better results than Merck's Keytruda, the current standard of care. 如果在关键市场获得批准，ivonescimab 可能会对 Keytruda 的销售产生重大影响，从而可能有利于 Summit 的财务前景。 If approved in key markets, ivonescimab could significantly impact Keytruda's sales, potentially benefiting Summit's financial outlook. 然而,投资仍然有风险。 However, the investment remains risky.